Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | SVP-Chief Financial Officer | August 18, 2020 | August 19, 2020 |
| Wejo Group LtdWEJO · Entity 113211 | Director · Chief Financial Officer | November 19, 2022 | November 21, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aquestive Therapeutics, Inc.
Report date August 18, 2020 · Filed August 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 150,614 |
Reported balance
After 2020-08-18 transaction · row 1
1 source rowRow 1 · 2020-08-18 · Sale · Disposed 3,000 · Balance 150,614 F1: The sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 16, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 16, 2020.
Wejo Group Ltd
Report date November 19, 2022 · Filed November 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 440,593 |
Reported balance
After 2022-11-19 transaction · row 1
1 source rowRow 1 · 2022-11-19 · Tax withholding · Disposed 74,456 · Balance 440,593 F1: Represents common shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted share units. |
| Common SharesSEC Table I · non-derivative | IndirectHeld by Spouse | 36,757 |
Reported balance
Holding disclosure · report date 2022-11-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 36,757 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents common shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted share units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 19, 2022 Filed Nov 21, 2022 16:12 UTC | Wejo Group Ltd WEJO · Entity 113211 | Tax withholdingCommon Shares | 74,456 | $0.84 | $62,543.04 |
DisclosureSEC source: 0001864448-22-000101 · wf-form4_166906515194886.xml · nonDerivative · entry 1 Maxwell John T. · CIK 0001739025 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,593 F1 · kind: Represents common shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted share units. Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 16:18 UTC | Wejo Group Ltd WEJO · Entity 113211 | GrantWarrants (right to buy) · Derivative | 12,252 | $0.13 Strike: $1.56 | $1,531.50 |
DisclosureSEC source: 0001864448-22-000066 · wf-form4_165912586017785.xml · derivative · entry 4 Maxwell John T. · CIK 0001739025 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Spouse Disclosed balance after: 12,252 Underlying: Common Shares · 12,252 shares Expires 2027-07-29 F2 · security: Warrants purchased from the Company in the Private Placement. Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 16:18 UTC | Wejo Group Ltd WEJO · Entity 113211 | GrantWarrants (right to buy) · Derivative | 12,252 | $0.13 Strike: $1.56 | $1,531.50 |
DisclosureSEC source: 0001864448-22-000066 · wf-form4_165912586017785.xml · derivative · entry 3 Maxwell John T. · CIK 0001739025 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,252 Underlying: Common Shares · 12,252 shares Expires 2027-07-29 F2 · security: Warrants purchased from the Company in the Private Placement. Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 16:18 UTC | Wejo Group Ltd WEJO · Entity 113211 | GrantCommon Shares | 36,757 | $1.36 | $50,000.55 |
DisclosureSEC source: 0001864448-22-000066 · wf-form4_165912586017785.xml · nonDerivative · entry 2 Maxwell John T. · CIK 0001739025 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Spouse Disclosed balance after: 36,757 F1 · security: Common Shares purchased from Wejo Group Limited (the "Company") in a private placement of an aggregate of 11,329,141 of the Company's Units (as defined below), each consisting of (i) one of theCompany's common shares (the "Shares") and (ii) one third of one warrant to purchase one Share (the "Warrants," and together with the Shares, the "Units") at a purchase price of $1.40197 per Unit (the "Private Placement"). The Reporting Person's purchase of the Units was approved by the Company's Board of Directors. Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 16:18 UTC | Wejo Group Ltd WEJO · Entity 113211 | GrantCommon Shares | 36,757 | $1.36 | $50,000.55 |
DisclosureSEC source: 0001864448-22-000066 · wf-form4_165912586017785.xml · nonDerivative · entry 1 Maxwell John T. · CIK 0001739025 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 515,049 F1 · security: Common Shares purchased from Wejo Group Limited (the "Company") in a private placement of an aggregate of 11,329,141 of the Company's Units (as defined below), each consisting of (i) one of theCompany's common shares (the "Shares") and (ii) one third of one warrant to purchase one Share (the "Warrants," and together with the Shares, the "Units") at a purchase price of $1.40197 per Unit (the "Private Placement"). The Reporting Person's purchase of the Units was approved by the Company's Board of Directors. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 12:55 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 3,000 | $8.00 | $24,000.00 |
DisclosureSEC source: 0001214659-20-007366 · marketforms-49485.xml · nonDerivative · entry 1 Maxwell John T. · CIK 0001739025 · SVP-Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,614 F1 · kind: The sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 16, 2020. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:47 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001214659-20-002751 · marketforms-48345.xml · derivative · entry 1 Maxwell John T. · CIK 0001739025 · SVP-Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-03-16 F1 · derivative.exercise_date: The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:45 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 95,000 | $0.00 Strike: $8.05 | $0.00 |
DisclosureSEC source: 0001214659-19-001749 · marketforms-44355.xml · derivative · entry 1 Maxwell John T. · CIK 0001739025 · SVP-Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 21:27 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 5,000 | $8.87 | $44,350.00 |
DisclosureSEC source: 0001140361-18-044723 · form4.xml · nonDerivative · entry 1 Maxwell John T. · CIK 0001739025 · SVP-Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,614 F1 · ownership.direct: Includes 10,000 shares owned jointly with Mr. Maxwell's spouse. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 18:39 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 10,000 | $9.80 | $98,000.00 |
DisclosureSEC source: 0001140361-18-043653 · form4.xml · nonDerivative · entry 1 Maxwell John T. · CIK 0001739025 · SVP-Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,614 F1 · ownership.direct: Includes 10,000 shares owned jointly with Mr. Maxwell's spouse. Read SEC document |
| July 24, 2018 Filed Jul 27, 2018 01:12 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 36,120 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001140361-18-033743 · form4.xml · derivative · entry 1 Maxwell John T. · CIK 0001739025 · SVP-Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,120 Underlying: Common Stock · 36,120 shares Expires 2028-07-24 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 25% of the underlying shares vest on the first anniversary of the grant date, 25% of the underlying shares vest on the second anniversary of the grant date and the remaining 50% of the underlying shares vest on the third anniversary of the grant date, subject in each case to Mr. Maxwell's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.